Comparison · NCT00524368-66e55d36
DRV/Rtv 800/100 mg Once Daily vs DRV/Rtv 600/100 mg Twice Daily: Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DRV/Rtv 800/100 mg Once Daily vs DRV/Rtv 600/100 mg Twice Daily: Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm. Trial comparisons, record NCT00524368-66e55d36. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00524368-66e55d36
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.721 | 0.667 | 0.769 | wilson | |
| Risk in group 2 | 0.709 | 0.655 | 0.758 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0116 | -0.061 | 0.0841 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.918 | 1.13 | log | |
| Odds ratio, group 1 over group 2 | 1.06 | 0.74 | 1.51 | log | |
| Number needed to treat, for one more participant with the outcome on DRV/Rtv 800/100 mg Once Daily than on DRV/Rtv 600/100 mg Twice Daily | 86 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DRV/Rtv 800/100 mg Once Daily | Two 400 mg tablets of darunavir (DRV) + one 100 mg capsule of ritonavir (rtv) once daily | 212 | 294 | OG000 |
| Group 2 | DRV/Rtv 600/100 mg Twice Daily | One 600 mg darunavir (DRV) tablet + one 100 mg capsule of ritonavir (rtv) given twice daily | 210 | 296 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
- Description
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response. In all other cases, intermittent values were imputed with nonresponse. Resuppression after confirmed virologic failure was considered as failure in this algorithm.
- Time frame
- 48 Weeks
- Population
Intention To Treat (ITT) population: Participants who permanently discontinued were considered nonresponders after discontinuation. Participants with intermittent missing viral load values were considered responders if preceeding and succeeding visits indicated response. Otherwise, intermittent values were imputed with nonresponse.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
- NCT number
- NCT00524368
- Phases
- PHASE3
- Conditions
- Human Immunodeficiency Virus - Type 1
- Interventions
- Darunavir (DRV), Ritonavir (rtv)
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Results first posted
- 2010-09-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00524368?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00524368-66e55d36